Unlocking the biopharma development pipeline
The current drug and therapeutic development process can be complex, time-consuming and resource-intensive. One major bottleneck is the reliance on a wide range of conventional assays and analytical tools, which have inherent limitations that reduce efficiency, accuracy, scalability and decision-making.
In this introductory guide, discover how a new generation of molecular sensing technology is transforming each stage of the biopharma development process, streamlining progress from early research to clinical development.
Oxford Nanopore sequencing, developed by Oxford Nanopore Technologies (Oxford, UK), is a high-resolution, single-platform molecular sensing solution that generates ultra-rich, multiomic data, suitable for:
- Novel biomarker discovery and target identification
- Candidate identification
- Construct characterization
- Expression optimization
- Viral vector characterization
- Cell line development
- Quality control release testing
- Clinical development and post-market surveillance
This content was provided by Oxford Nanopore.
